Evidence map›Paper›PMID 42733245›Full record

ReviewAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Leveraging Microphysiological Systems to Facilitate Neutrophil-Based Cancer Immunotherapy.

Shuai Shao, Markus Isfeld Diehl, Caroline N Jones

Abstract readReview
In one paragraph

Review in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Shuai ShaoDepartment of Bioengineering, The University of Texas at Dallas, Richardson, Texas, USA.ORCID https://orcid.org/0000-0002-7869-7990
Markus Isfeld DiehlProgram in Immunology, Stanford University, Stanford, California, USA.ORCID https://orcid.org/0000-0001-5402-2350
Caroline N JonesDepartment of Bioengineering, The University of Texas at Dallas, Richardson, Texas, USA.ORCID https://orcid.org/0000-0001-6003-9335

Funding

2025 Bioengineering Convergent Grant at the University of Texas at DallasEugene McDermott Distinguished ProfessorshipJonsson School Research Initiative (JSRI) at the University of Texas at DallasNational Science Foundation (NSF) CBET CAREER 2240094
6 · The paper itself

Abstract

Neutrophils are the most abundant immune cells in human blood and serve as the first line of defense against infection. However, the role of neutrophils in cancer progression is complex and context-dependent, and they are underexplored as therapeutic targets for cancer compared with other immune cell types. Microphysiological systems, also known as complex in vitro models, have emerged as powerful tools for deciphering immune cell-cancer interactions and preclinical drug testing due to the advantages of real-time visualization of cell behaviors, precise control of microenvironments, and incorporation of human cells over in vivo animal models. This review first summarizes the multifaceted roles of neutrophils in cancer as defined by in vivo animal models and highlights recently developed strategies to mobilize neutrophils for cancer treatment. Next, current applications of different types of microphysiological systems, including 3D spheroids, organoids, and microfluidic organ-on-a-chip platforms, for investigating the role of human neutrophils in cancer and evaluating neutrophil-based cancer immunotherapies are surveyed. Lastly, future opportunities for microphysiological systems to address key challenges in the clinical translation of neutrophil-based cancer immunotherapy are discussed.

Indexed as

cancerimmunotherapymicrophysiological systemneutrophilorgan‐on‐a‐chip

Identifiers

PMID42733245
PMCPMC13572835

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.